A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan.

Diaby V, Alqhtani H, van Boemmel-Wegmann S, Wang CY, Ali AA, Balkrishnan R, Ko Y, Palacio S, de Lima Lopes G. A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan. Breast. 2020 Feb; 49:141-148.

View in: PubMed

subject areas

Adult
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Cost-Benefit Analysis
Female
Humans
Markov Chains
Middle Aged
Neoplasm Metastasis
Quality-Adjusted Life Years
Receptor, erbB-2
Taiwan

authors with profiles

Vakaramoko Diaby

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support